Carolina Vitale

Salerno, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Assessing response to biological therapies in severe asthma.

Assessing response to biological therapies in severe asthma.

Journal: Expert review of clinical immunology

Published: April 03, 2026

Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.

Plasma miR-1-3p levels predict severity in hospitalized COVID-19 patients.

Journal: British journal of pharmacology

Published: August 10, 2024

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.

Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 14, 2024

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.

Journal: International journal of molecular sciences

Published: January 02, 2023

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting.

Journal: Journal of clinical medicine

Published: December 19, 2022

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma.

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma.

Journal: Biomedicines

Published: August 10, 2022

Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β.

Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β.

Journal: Frontiers in immunology

Published: May 02, 2022

Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy).

Untargeted lipidomics reveals specific lipid profiles in COVID-19 patients with different severity from Campania region (Italy).

Journal: Journal of pharmaceutical and biomedical analysis

Published: February 21, 2022

Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems.

Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems.

Journal: Journal of clinical medicine

Published: December 17, 2021

Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β.

Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β.

Journal: Biomedicines

Published: November 04, 2021

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma.

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma.

Journal: Biomedicines

Published: September 27, 2021

Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art.

Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art.

Journal: Expert opinion on pharmacotherapy

Published: May 28, 2020

Showing 1-12 of 33

Last Updated: 09/26/2026